These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39026980)

  • 21. Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer.
    Lu J; Lei X; Zhang P; Du L; Zhang Z; Qu B
    Cancer Med; 2023 Sep; 12(17):17924-17933. PubMed ID: 37563966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials.
    Facchinetti F; Di Maio M; Tiseo M
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
    JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.
    Liang H; Lin G; Wang W; Huang J; Yang Y; Lan Y; Wang R; Cui F; Hao Z; Deng H; Zhao S; Cheng B; Xiong S; Li J; Li C; Liu J; He J; Liang W
    Transl Lung Cancer Res; 2020 Apr; 9(2):188-203. PubMed ID: 32420059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Wang BC; Xiao BY; Li PC; Kuang BH; Chen WB; Li PD; Lin GH; Liu Q
    J Oncol; 2020; 2020():2368164. PubMed ID: 33061969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of immunotherapy combined with chemotherapy in patients with ES-SCLC: A systematic review and network meta-analysis of RCTs and RWSs.
    Kang R; Ma J; Ai B; Liu J; Zheng Z; Yu J
    Thorac Cancer; 2024 Oct; ():. PubMed ID: 39397360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
    Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q
    Front Immunol; 2022; 13():1059995. PubMed ID: 36569915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region.
    Wu Y; Yang J; Qiao X; Li Y; Zhao R; Lin T; Li X; Wang M
    Front Oncol; 2023; 13():1041140. PubMed ID: 37007079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials.
    Li X; Yan S; Yang J; Wang Y; Lv C; Li S; Zhao J; Yang Y; Zhuo M; Wu N
    Front Oncol; 2020; 10():574752. PubMed ID: 33585195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials.
    Duan X; Du H; Qi R; Yuan M; Shi J
    Exp Ther Med; 2023 May; 25(5):216. PubMed ID: 37123204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
    Wang BC; Fu C; Lin GH
    Front Immunol; 2023; 14():1185577. PubMed ID: 37215120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
    Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D
    J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
    Mo DC; Huang JF; Luo PH; Chen L; Zou B; Wang HL
    Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):1-9. PubMed ID: 35907001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review.
    Yang YL; Li ZQ; Wang QL; Gu JJ; Fang XJ; Huang GH
    Clin Ther; 2021 Nov; 43(11):1997-2012. PubMed ID: 34794831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.
    Alifu M; Tao M; Chen X; Chen J; Tang K; Tang Y
    Front Oncol; 2023; 13():1146905. PubMed ID: 37397392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysis.
    Teo AYT; Yau CE; Low CE; Pereira JV; Ng JYX; Soong TK; Lo JYT; Yang VS
    EClinicalMedicine; 2024 Nov; 77():102870. PubMed ID: 39416390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
    Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.